Eloralintide vs SS-31 (Elamipretide)
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
EloralintideAnti-Aging & Longevity
SS-31 (Elamipretide)- Summary
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
- Half-Life
- ~7 days (estimated, long-acting design)
- ~2–5 hours
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- Under investigation in Phase 1/2 trials
- 5–10 mg
- Frequency
- Once weekly
- Daily to several times per week
- Key Benefits
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Restores mitochondrial function and ATP production
- Protects inner mitochondrial membrane cardiolipin
- Reduces mitochondrial reactive oxygen species (ROS)
- Improves exercise capacity and reduces fatigue
- Cardioprotective — studied in heart failure trials
- Renoprotective — reduces ischemic kidney injury
- Anti-aging via mitochondrial preservation
- Potential in neurodegenerative disease prevention
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Injection site irritation
- Nausea (rare)
- Generally well-tolerated in clinical trials
- Stacks With
- —
- —